ILE Isolagen

EXTON, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) announced today that it has engaged Skadden, Arps, Slate, Meagher & Flom, LLP to represent the Company and other of the defendants named in the various class action suits. The Company does not expect to respond to the suits until there has been a consolidation of the complaints and lead plaintiff is selected at which time the Company expects to file a motion to dismiss the claims. ABOUT ISOLAGEN, INC. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein. DATASOURCE: Isolagen, Inc. CONTACT: Lee M. Stern, ext. 22, or Marcy Strickler, ext. 27, both of The Trout Group, +1-212-477-9007, for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright